359-85-3

Basic information

• Product Name: 2H-1,2,4-Benzothiadiazine 1,1-dioxide
• Synonyms: 2H-1,2,4-Benzothiadiazine 1,1-dioxide;4H-1,2,4-Benzothiadiazine 1,1-dioxide
• CAS NO: 359-85-3
• Molecular Formula: C₇H₆N₂O₂S
• Molecular Weight: 182.1997
• Mol File: 359-85-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 380.1°Cat760mmHg
• Flash Point: 183.7°C
• Appearance: /
• Density: 1.54g/cm³
• Vapor Pressure: 5.59E-06mmHg at 25°C
• Refractive Index: 1.7
• CAS DataBase Reference: 2H-1,2,4-Benzothiadiazine 1,1-dioxide(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-1,2,4-Benzothiadiazine 1,1-dioxide(359-85-3)
• EPA Substance Registry System: 2H-1,2,4-Benzothiadiazine 1,1-dioxide(359-85-3)

Safety Data

• Hazardous Substances Data: 359-85-3(Hazardous Substances Data)

Usage

General Description

2H-1,2,4-Benzothiadiazine 1,1-dioxide, also known as bendroflumethiazide, is a thiazide diuretic medication used to treat high blood pressure and fluid retention. It works by increasing the excretion of sodium and water from the body, leading to a decrease in blood volume and a reduction in blood pressure. Bendroflumethiazide is taken orally and is available in tablet form. It is generally well-tolerated but may cause side effects such as dizziness, headache, and electrolyte imbalances. It is important to follow the dosage and directions provided by a healthcare professional when taking this medication. Bendroflumethiazide should not be used in individuals with severe kidney impairment or those who are allergic to sulfonamide-derived drugs.

InChI:InChI=1/C7H6N2O2S/c10-12(11)7-4-2-1-3-6(7)8-5-9-12/h1-5H,(H,8,9)

Upstream product

• 50-00-0 formaldehyd 
• 3306-62-5 2-AMINOBENZENESULFONAMIDE 
• 67-56-1 methanol 
• 122-51-0 orthoformic acid triethyl ester 
• 149-73-5 trimethyl orthoformate 
• 119072-55-8 tert-butylisonitrile 
• 62-53-3 aniline 
• 13338-00-6 2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide 
• 72357-88-1 2-benzyl-2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide 
• 5455-59-4 2-Nitrobenzenesulfonamide 

Downstream Products

• 37162-46-2 7-bromo-4H-1,2,4-benzothiadiazine 1,1-dioxide 
• 2250-41-1 2--2H-1.2.4-benzothiadiazin-1.1-dioxid 
• 554-68-7 triethylamine hydrochloride 
• 933024-24-9 4-(4-bromo-2-fluorobenzyl)-4H-1,2,4-benzothiadiazine 1,1-dioxide 
• 1256768-90-7 4-[4-(trifluoromethyl)benzyl]-4H-1,2,4-benzothiadiazine 1,1-dioxide 
• 896796-17-1 4-(3-nitrobenzyl)-4H-1,2,4-benzothiadiazine 1,1-dioxide 
• 1256768-91-8 4-(2,4,5-trifluorobenzyl)-4H-1,2,4-benzothiadiazine 1,1-dioxide 
• 359-84-2 3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-1,1-dioxide 

Relevant articles and documents

Synthesis and in vitro antileishmanial efficacy of novel quinazolinone derivatives

Currently available drugs being used to treat leishmaniasis have several shortcomings, including high toxicity, drug administration that requires hospitalization, and the emergence of parasite resistance against clinically used drugs. As a result, there is a dire need for the development of new antileishmanial drugs that are safe, affordable, and efficient. In this study, two new series of synthesized quinazolinone derivatives were investigated as potential future antileishmanial agents, by assessing their activities against the Leishmania (L.) donovani and L.?major species. The cytotoxicity profiles of these derivatives were assessed in vitro on Vero cells. The compounds were found to be safer and without any toxic activities against mammalian cells, compared to the reference drug, halofuginone, a clinical derivative of febrifugine. However, they had demonstrated poor antileishmanial growth inhibition efficacies. The two compounds that had been found the most active were the mono quinazolinone 2d and the bisquinazolinone 5b with growth inhibitory efficacies of 35% and 29% for the L.?major and L.?donovani 9515 promastigotes, respectively. These outcomes had suggested structural redesign, inter alia the inclusion of polar groups on the quinazolinone ring, to potentially generate novel quinazolinone derivatives, endowed with effective antileishmanial potential.

Benzothiadiazine methoxy acrylate derivatives and preparation method and application thereof

The invention provides benzothiadiazine methoxy acrylate derivatives and a preparation method and application thereof, and the benzothiadiazine methoxy acrylate derivatives have the following chemicalstructural general formula VII as shown in the description, wherein R1 is hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, methoxy or nitro; and R2 is hydrogen, methyl or benzyl. According to the invention, an active group 3, 4-dihydro-2H-1, 2, 4-benzothiadiazine-1, 1-dioxo substitutes the side chain part of the methoxy acrylate bactericide and then is reasonably spliced with the pharmacophore of the methoxy acrylate bactericide, so that the bactericide with novel structure, broad spectrum, high efficiency and low toxicity is synthesized, the bactericide can be alternately used with the existing bactericide, the generation of resistance is avoided or delayed, the preparation conditions are conventional, the subsequent treatment is simple and convenient, and the industrialization is easy to realize.

Benzothiadiazine derivatives as well as preparation method and application thereof

The invention discloses benzothiadiazine derivatives as well as preparation methods and application thereof. The compounds have the structures of formula I or II. The invention also relates to preparation methods of the compounds containing the structures of formula I or II, pharmaceutical compositions and the application of the compounds in the preparation of anti-HBV drugs. The formula I or II are shown in the description.